Eli Lilly said on Friday that the European Medicines Agency (EMA) has recommended approval of its drug Kisunla for certain ...

Biogen has started a new phase 3 trial that aims to extend the use of its Friedreich's ataxia drug Skyclarys to patients as young as two.

People living with hereditary angioedema (HAE) often find themselves in a cycle of stress about when the next attack might appear, which may trigger more episodes. Read more.